KURA ONCOLOGY, INC. Current Portion of Long-Term Debt
KURA ONCOLOGY, INC. (KURA) had Current Portion of Long-Term Debt of $4.22 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LongTermDebtCurrent · last filed 2026-08-12
- 2026-06-30: Long-term Debt, Current Maturities $4.22M.
- 2025-12-31: Long-term Debt, Current Maturities $0.00.
- 2025-09-30: Long-term Debt, Current Maturities $4.34M.
- 2025-06-30: Long-term Debt, Current Maturities $3.11M.
| Period end | Long-term Debt, Current Maturities |
|---|---|
| 2026-06-30 | $4.22M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-12 |
| 2025-09-30 | $4.34M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $3.11M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.92M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.61M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.72M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $847.00K 10-Q · filed 2024-08-08 |
| 2021-03-31 | $3.00M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $3.00M 10-K · filed 2022-02-24 |
| 2020-09-30 | $2.50M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.75M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.00M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $250.00K 10-K · filed 2021-02-24 |
| 2018-09-30 | $2.83M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $2.81M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $2.29M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $1.53M 10-K · filed 2019-03-05 |
| 2017-09-30 | $1.02M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $500.00K 10-Q · filed 2017-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |